Press Room https://stage.mediaroom.com/sanofi/ MediaRoom Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease https://stage.mediaroom.com/sanofi/2026-05-28-Sanofis-venglustat-accepted-for-priority-review-in-the-US-to-treat-type-3-Gaucher-disease Thu, 28 May 2026 01:00:00 -0400 https://stage.mediaroom.com/sanofi/2026-05-28-Sanofis-venglustat-accepted-for-priority-review-in-the-US-to-treat-type-3-Gaucher-disease ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD https://stage.mediaroom.com/sanofi/2026-05-18-ATS-phase-2-data-demonstrate-the-superiority-of-efdoralprin-alfa-over-a-standard-of-care-augmentation-therapy-in-achieving-higher-fAAT-levels-in-AATD Mon, 18 May 2026 15:47:00 -0400 https://stage.mediaroom.com/sanofi/2026-05-18-ATS-phase-2-data-demonstrate-the-superiority-of-efdoralprin-alfa-over-a-standard-of-care-augmentation-therapy-in-achieving-higher-fAAT-levels-in-AATD DDW: Sanofi and Regeneron’s DUPIXENT® demonstrates improved esophageal function in eosinophilic esophagitis phase 4 study https://stage.mediaroom.com/sanofi/2026-05-05-DDW-Sanofi-and-Regenerons-DUPIXENT-R-demonstrates-improved-esophageal-function-in-eosinophilic-esophagitis-phase-4-study Tue, 05 May 2026 07:00:00 -0400 https://stage.mediaroom.com/sanofi/2026-05-05-DDW-Sanofi-and-Regenerons-DUPIXENT-R-demonstrates-improved-esophageal-function-in-eosinophilic-esophagitis-phase-4-study Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria https://stage.mediaroom.com/sanofi/2026-04-22-Sanofi-and-Regenerons-Dupixent-approved-in-the-US-as-the-first-biologic-medicine-for-young-children-with-uncontrolled-chronic-spontaneous-urticaria Wed, 22 Apr 2026 17:30:00 -0400 https://stage.mediaroom.com/sanofi/2026-04-22-Sanofi-and-Regenerons-Dupixent-approved-in-the-US-as-the-first-biologic-medicine-for-young-children-with-uncontrolled-chronic-spontaneous-urticaria Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children https://stage.mediaroom.com/sanofi/2026-04-22-Sanofis-Tzield-approved-in-the-US-to-delay-the-onset-of-stage-3-type-1-diabetes-in-young-children Wed, 22 Apr 2026 01:05:00 -0400 https://stage.mediaroom.com/sanofi/2026-04-22-Sanofis-Tzield-approved-in-the-US-to-delay-the-onset-of-stage-3-type-1-diabetes-in-young-children